Media coverage about Incyte (NASDAQ:INCY) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Incyte earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.8207404300389 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- Incyte Targeted Therapy and Immuno-Oncology Portfolio to be Featured in 15 Abstracts at the AACR Annual Meeting 2018 (markets.financialcontent.com)
- Incyte (INCY) Lifted to Sell at BidaskClub (americanbankingnews.com)
- Incyte Co. (INCY) Receives Average Recommendation of “Buy” from Analysts (americanbankingnews.com)
- Merck to Pay $300M Upfront to Co-Develop Eisai’s Cancer Drug – Nasdaq (nasdaq.com)
- Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights – GlobeNewswire (press release) (globenewswire.com)
A number of equities analysts have commented on the company. Deutsche Bank began coverage on Incyte in a research note on Tuesday, December 12th. They issued a “hold” rating and a $106.00 target price for the company. Oppenheimer reiterated a “hold” rating and set a $110.00 price objective (down from $120.00) on shares of Incyte in a research report on Monday, January 22nd. Zacks Investment Research downgraded Incyte from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Credit Suisse Group set a $145.00 target price on Incyte and gave the stock a “buy” rating in a research report on Wednesday, February 14th. Finally, Citigroup restated a “market perform” rating and issued a $120.00 target price (down from $135.00) on shares of Incyte in a research report on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $142.83.
Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.54. Incyte had a negative net margin of 20.38% and a negative return on equity of 11.85%. The firm had revenue of $444.20 million during the quarter, compared to analyst estimates of $435.23 million. During the same quarter in the prior year, the business posted $0.05 earnings per share. The company’s quarterly revenue was up 36.0% compared to the same quarter last year. equities research analysts predict that Incyte will post -0.28 earnings per share for the current year.
In other news, insider David W. Gryska sold 6,760 shares of the stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $98.87, for a total transaction of $668,361.20. Following the sale, the insider now directly owns 20,752 shares of the company’s stock, valued at $2,051,750.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David W. Gryska sold 1,952 shares of the stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $85.56, for a total transaction of $167,013.12. Following the sale, the insider now directly owns 12,922 shares in the company, valued at $1,105,606.32. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,670 shares of company stock valued at $1,489,181. Company insiders own 17.70% of the company’s stock.
WARNING: “Incyte (INCY) Receives Media Sentiment Rating of 0.18” was first published by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://baseballnewssource.com/2018/03/15/incyte-incy-receiving-somewhat-positive-media-coverage-analysis-finds/1983808.html.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.